{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:31:06Z","timestamp":1761561066276},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1007\/s11239-006-7454-8","type":"journal-article","created":{"date-parts":[[2006,6,19]],"date-time":"2006-06-19T09:23:16Z","timestamp":1150708996000},"page":"47-50","source":"Crossref","is-referenced-by-count":25,"title":["Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina"],"prefix":"10.1007","volume":"22","author":[{"given":"Albert J.","family":"Deibele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay J.","family":"Kirtane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duane S.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Lucca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Neva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Shui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabina A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Tcheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"7454_CR1","doi-asserted-by":"crossref","unstructured":"Enhanced suppression of the platelet IIb\/IIIareceptor with integrilin therapy (ESPRIT) investigators (2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo controlled trial. Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy. Lancet 356:2037\u20132044","DOI":"10.1016\/S0140-6736(00)03400-0"},{"key":"7454_CR2","doi-asserted-by":"crossref","unstructured":"Integrilin to minimise platelet aggregation and coronary thrombosis-II (IMPACT II) investigators (1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 349:1422\u20131428","DOI":"10.1016\/S0140-6736(96)10172-0"},{"key":"7454_CR3","doi-asserted-by":"crossref","unstructured":"Evaluation of platelet IIb\/IIIa inhibitor for stenting (EPISTENT) investigators (1998) Randomized placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of glycoprotein IIb\/IIIa blockade. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting. Lancet 352:87\u201392","DOI":"10.1016\/S0140-6736(98)06113-3"},{"key":"7454_CR4","doi-asserted-by":"crossref","unstructured":"Evaluation in PTCA to improve long-term outcome with abciximab gp IIb\/IIIa blockade (EPILOG) investigators (1997) Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689\u20131696","DOI":"10.1056\/NEJM199706123362401"},{"key":"7454_CR5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/00005344-200304000-00011","volume":"41","author":"M Moser","year":"2003","unstructured":"Moser M, Bertram U, Peter K, Bode C, Ruef J. (2003) Abciximab, Eptifibatide, Tirofiban Exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovasc Pharmacol 41:586\u2013592","journal-title":"J Cardiovasc Pharmacol"},{"key":"7454_CR6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2004.02.059","volume":"44","author":"S Goto","year":"2004","unstructured":"Goto S, Tamura N, Ishida H (2004) Ability of anti-glycoprotein IIb\/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44:316\u2013323","journal-title":"J Am Coll Cardiol"},{"key":"7454_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/01.CIR.0000137912.11655.F6","volume":"110","author":"CM Gibson","year":"2004","unstructured":"Gibson CM, Jennings LK, Murphy SA, et al (2004) Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction. an INTEGRITI (integrilin and tenecteplase in acute myocardial infarction) substudy. Circulation 110:679\u2013684","journal-title":"Circulation"},{"key":"7454_CR8","first-page":"932","volume":"312","author":"Thrombolysis in Myocardial Infarction (TIMI) study group","year":"1985","unstructured":"Thrombolysis in Myocardial Infarction (TIMI) study group (1985) The thrombolysis in myocardial infarction (TIMI) trial. phase I findings. N Engl J Med 312:932\u2013936","journal-title":"N Engl J Med"},{"key":"7454_CR9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","volume":"93","author":"CM Gibson","year":"1996","unstructured":"Gibson CM, Cannon CP, Daley WL, et al (1996) TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93:879\u2013888","journal-title":"Circulation"},{"key":"7454_CR10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1161\/01.CIR.101.2.125","volume":"101","author":"CM Gibson","year":"2000","unstructured":"Gibson CM, Cannon CP, Murphy SA, et al (2000) Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 101:125\u2013130","journal-title":"Circulation"},{"key":"7454_CR11","unstructured":"Gibson CM. (2004) A randomized trial to evaluate the relative protection against post-PCI microvascular dysfunction and post-PCI ischemia among anti-platelet and anti-thrombotic agents. New Orleans: Texas Heart Symposium."},{"key":"7454_CR12","unstructured":"Mitchel JF, Alberghini TV (1996) Site-specific thrombolysis with reopro. Circulation 94:I202"},{"key":"7454_CR13","first-page":"I202","volume":"94","author":"JF Mitchel","year":"1996","unstructured":"Mitchel JF, Alberghini TV (1996) Local delivery of reopro: pharmacokinetics and effect on platelet deposition following balloon angioplasty. Circulation 94:I202","journal-title":"Circulation"},{"key":"7454_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/(SICI)1097-0304(199710)42:2<181::AID-CCD18>3.0.CO;2-R","volume":"42","author":"SR Bailey","year":"1997","unstructured":"Bailey SR, O\u2019Leary E, Chilton R (1997) Angioscopic evaluation of site-specific administration of reopro. Catheter Cardiovasc Diagn 42:181\u2013184","journal-title":"Catheter Cardiovasc Diagn"},{"key":"7454_CR15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/(SICI)1522-726X(199910)48:2<211::AID-CCD20>3.0.CO;2-V","volume":"48","author":"AL Bartorelli","year":"1999","unstructured":"Bartorelli AL, Trabattoni D, Galli S, Grancini L, Cozzi S, Ravagnani P (1999) Successful dissolution of occlusive thrombus with local administration of abciximab during PTCA. Catheter Cardiovasc Interv 48:211\u2013213","journal-title":"Catheter Cardiovasc Interv"},{"key":"7454_CR16","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/01.CIR.0000066852.98038.D1","volume":"107","author":"J W\u00f6hrle","year":"2003","unstructured":"W\u00f6hrle J, Grebe OC, Nusser T, et al (2003) Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction on unstable angina undergoing coronary angioplasty. Circulation 107:1840\u20131843","journal-title":"Circulation"},{"key":"7454_CR17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ccd.10730","volume":"61","author":"AK Kakkar","year":"2004","unstructured":"Kakkar AK, Moustapha A, Hanley HG, et al. (2004) Comparison of intracoronary vs intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 61:31\u201334","journal-title":"Catheter Cardiovasc Interv"},{"key":"7454_CR18","unstructured":"Physicians\u2019 Desk Reference (2005). 59th Edition. Montvale, NJ, Medical Economics Company, pp. 2203\u20132207"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-006-7454-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-006-7454-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-006-7454-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:01:32Z","timestamp":1559386892000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-006-7454-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["7454"],"URL":"https:\/\/doi.org\/10.1007\/s11239-006-7454-8","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]}}}